MISSISSAUGA, ON – GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy (carboplatin and paclitaxel) for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy.[1] This approval broadens the previous indication for Jemperli in combination with carboplatin and paclitaxel to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represents approximately 75% [2] of patients diagnosed with endometrial cancer and who have limited treatment options.
\n\"Today's expanded approval of Jemperli for all patients with primary advanced or first recurrent endometrial cancer in Canada is supported by an overall survival benefit across the study population. This represents a significant milestone and demonstrates Jemperli’s potential to redefine the treatment of cancers with high mortality rates and unmet needs, such as endometrial cancer,\" said Michelle Horn, Country Medical Director at GSK Canada. \"Jemperli remains a backbone of our immuno-oncology program, offering renewed hope to Canadian patients and emphasizing GSK's dedication, as a research-focused company, to addressing the most common gynaecologic cancer in Canada.\"
\nHealth Canada’s approval to expand the use of Jemperli is based on results from Part 1 of the RUBY phase III trial. RUBY Part 1 met its dual primary endpoints of Progression-Free Survival (PFS) and Overall Survival (OS) in the overall population of patients with primary advanced or recurrent endometrial cancer, and is the only clinical trial in this setting to show a clinically meaningful and statistically significant OS benefit, demonstrating a 31% reduction in risk of death (HR: 0.69; 95% CI: 0.54–0.89, p=0.002, n=494) compared to chemotherapy alone.
\n\"Gynaecological oncologists have long awaited an immuno-oncology option to improve survival outcomes for endometrial cancer patients at advanced stages, and newly approved treatments in Canada enhance the cancer care journey by offering more personalized options,\" says Dr. Alon Altman, Gynecologic Oncologist and Professor of Obstetrics and Gynecology at the University of Manitoba, and Chief Strategy Officer and Former President of The Society of Gynecologic Oncology of Canada (GOC). \"Ensuring innovative clinical therapies are publicly available and accessible to all patients in need is also vital as timely treatment is especially crucial for individuals with more advanced endometrial cancer who cannot afford to wait.\"
\nThe expanded approval follows Jemperli’s November 2023 approval in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on an earlier analysis of Part 1 of the RUBY study.
\nFilomena Servidio-Italiano, President & CEO of the Colorectal Cancer Resource & Action Network (CCRAN), a patient advocacy group dedicated to improving the longevity and quality of life for all cancer patients in Canada, stated, “The expanded approval of dostarlimab provides patients with advanced or recurrent endometrial cancer new hope of extending their lives. Patients and advocates should be encouraged by this announcement, offering a new treatment option to patients in Canada diagnosed with endometrial cancer. We are optimistic that the Canadian reimbursement and funding systems will support the accessibility of this important therapy for those in need.\"
\nAbout endometrial cancer
\nEndometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is the most common gynaecologic cancer in developed countries,[3] with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each year worldwide.[4] Incidence rates are expected to rise by approximately 40% between 2020 and 2040.[5] In Canada, an estimated 8,600 women were diagnosed with endometrial cancer in 2024, with approximately 1,600 succumbing to the disease.[6] Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.[7] Among patients with primary advanced or recurrent endometrial cancer, approximately 75% have MMRp/MSS tumours.[2]
\nAbout RUBY
\nRUBY is a two-part global, randomized, double-blind, multicentre phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 evaluated dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo.
\nIn Part 1, the dual-primary endpoints are investigator-assessed PFS based on the Response Evaluation Criteria in Solid Tumours v1.1, and OS. The statistical analysis plan included pre-specified analyses of PFS in the dMMR/ MSI-H and overall populations and OS in the overall population. Pre-specified exploratory analyses of PFS and OS in the MMRp/MSS population and OS in the dMMR/MSI-H populations were also performed. RUBY Part 1 included 494 patients in efficacy analyses across a broad population, including histologies often excluded from clinical trials (approximately 10% of patients with carcinosarcoma and 20% with serous carcinoma).
\nAbout Jemperli (dostarlimab for injection)
\nJemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.[8]
\nIn Canada, Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy which includes patients with MMRp/MSS and dMMR/MSI-H tumours. Jemperli is also approved as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
\nPlease consult the Product Monograph at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
\nGSK in gynaecologic oncology
\nGSK is committed to maximizing patient survival through transformational medicines with a current effort on breakthroughs in oncology, including gynaecologic cancers, some of the most common cancers affecting women. We are focused on developing new medicines across a range of different modalities for a variety of cancers, including ovarian and endometrial.
\nAbout GSK
\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.ca.
\nReferences
\nSwitch to dark mode to head towards a more sustainable world together. More info.
"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"locationSelector":{"text":"Location selector","href":"/en-ca/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-ca/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-ca/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"At a glance","url":"/en-ca/company/at-a-glance/","nodes":[],"isActive":false},{"title":"Canada leadership team","url":"/en-ca/company/canada-leadership-team/","nodes":[],"isActive":false},{"title":"Policies","url":"/en-ca/company/policies/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global Outstanding people","image":{"src":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7504b0","alt":"Man smiling during a meeting","darkModeSrc":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7504b0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/outstanding-people/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global policy positions","image":{"src":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9142e6e0","alt":"Orange texture","darkModeSrc":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9142e6e0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/policy-positions","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-ca/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-ca/innovation/therapeutic-areas/","nodes":[],"isActive":false},{"title":"Trials","url":"/en-ca/innovation/trials/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global pipeline","image":{"src":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a91879100","alt":"Science experiment","darkModeSrc":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a91879100"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global Behind the science magazine","image":{"src":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8b311970","alt":"3D rendering of immuno-oncology cells","darkModeSrc":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8b311970"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/behind-the-science-magazine/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-ca/products/","nodes":[{"title":"Products A-Z","url":"/en-ca/products/products-a-z/","nodes":[],"isActive":false},{"title":"Stiefel - Dermatology","url":"/en-ca/products/stiefel-dermatology/","nodes":[],"isActive":false},{"title":"Report a possible side effect","url":"/en-ca/products/report-a-possible-side-effect/","nodes":[],"isActive":false},{"title":"Patient Support and Healthcare Support Services","url":"/en-ca/products/patient-support-and-healthcare-support-services/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Report a possible side effect","image":{"src":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=100&v=1dbf19a8dba8370","alt":"Woman in a labcoat smiling at the camera","darkModeSrc":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=90&v=1dbf19a8dba8370"},"link":{"text":"Featured section","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null}},{"text":"GSKPro","image":{"src":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=100&v=1dbf19a8e994ab0","alt":"Two people hanging out together in front of an orange background","darkModeSrc":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=90&v=1dbf19a8e994ab0"},"link":{"text":"Featured website","href":"https://gskpro.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-ca/responsibility/","nodes":[{"title":"Inclusion","url":"/en-ca/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-ca/responsibility/ethical-standards/","nodes":[{"title":"Engaging with healthcare professionals","url":"/en-ca/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false},{"title":"Transparency reporting","url":"/en-ca/responsibility/ethical-standards/transparency-reporting/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-ca/responsibility/ethical-standards/grants-and-donations/","nodes":[],"isActive":false}],"isActive":false},{"title":"Charitable investments in Canada","url":"/en-ca/responsibility/charitable-investments-in-canada/","nodes":[],"isActive":false},{"title":"Accessibility","url":"/en-ca/responsibility/accessibility/","nodes":[{"title":"GSK’s Multi-Year Accessibility Plan","url":"/en-ca/responsibility/accessibility/gsk-s-multi-year-accessibility-plan/","nodes":[],"isActive":false}],"isActive":false},{"title":"Patient group funding","url":"/en-ca/responsibility/patient-group-funding/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Ethical standards","image":{"src":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8db07150","alt":"Group working together in a lab","darkModeSrc":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8db07150"},"link":{"text":"Featured section","href":"/en-ca/responsibility/ethical-standards/","openInNewWindowText":null}},{"text":"Global responsibility","image":{"src":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=100&v=1dbf19a8dc8db50","alt":"Man adjusting glasses working on a computer","darkModeSrc":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=90&v=1dbf19a8dc8db50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/responsibility/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-ca/media/","nodes":[{"title":"Press releases","url":"/en-ca/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-ca/media/media-contacts/","nodes":[],"isActive":false},{"title":"Resource library","url":"/en-ca/media/resource-library/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Global press releases","image":{"src":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9120dff0","alt":"Artwork in GSK Building","darkModeSrc":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9120dff0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/media/press-releases/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-ca/careers/","nodes":[{"title":"Life at GSK","url":"/en-ca/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-ca/careers/experienced-professionals/","nodes":[],"isActive":false},{"title":"Early careers","url":"/en-ca/careers/early-careers/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global how we hire","image":{"src":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7fb310","alt":"People talking together in a meeting","darkModeSrc":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7fb310"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/how-we-hire/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global future leaders program","image":{"src":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=100&v=1dbf19a8f2d4d50","alt":"Two people conversing together in an office","darkModeSrc":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=90&v=1dbf19a8f2d4d50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","target":"_blank","openInNewWindowText":"Opens in a new window"}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=5769","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-ca/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This website is intended for visitors looking for information on GSK Canada. Other market sites can be reached by visiting our location selector.
\n© 2001-2026 GSK plc. All rights reserved. Trademarks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nGlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1
","modernSlaveryStatement":{"name":"GSK Modern Slavery Act Statement 2023","url":"/media/iwinetmy/modern-slavery-act-statement-2023.pdf","fileExtension":"PDF","fileSize":"154.2KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"https://twitter.com/gskca","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on X","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"GSK Global website","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Market website selector","href":"/en-ca/locations/","openInNewWindowText":null},{"text":"Global Behind the science magazine","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSKPro for healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK Medical for healthcare professionals","href":"https://medical.gsk.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Company","href":"/en-ca/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-ca/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-ca/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-ca/responsibility/","openInNewWindowText":null},{"text":"Media","href":"/en-ca/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-ca/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-ca/responsibility/accessibility/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Terms of use","href":"/en-ca/terms-of-use/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Cookie policy","href":"/en-ca/cookie-policy/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-ca/privacy-notice/general/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-ca/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy","og":[{"property":"og:title","content":"Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit for these patients "},{"property":"og:description","content":"GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy"},{"property":"og:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"property":"og:url","content":"https://ca.gsk.com/en-ca/media/press-releases/health-canada-expands-jemperli-dostarlimab-for-injection/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit for these patients "},{"name":"twitter:description","content":"GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy"},{"name":"twitter:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"name":"twitter:url","content":"https://ca.gsk.com/en-ca/media/press-releases/health-canada-expands-jemperli-dostarlimab-for-injection"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"You are leaving our website","texts":"The information you are about to be referred to may not comply with the local regulatory requirements. Further information relevant to the local environment is available from the company or via the Product Information.
","continueText":"Continue","cancelText":"Cancel","exclusionUrls":["http://gsk.com/","https://www.gsk.com","https://innovation.gsk.com/","https://www.gskgrants.com","https://www.gskforyou.com/","https://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","http://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","https://www.gsk.com/en-gb/products/stiefel-dermatology/","https://www.gsk.com/en-gb/products/viiv-healthcare/","https://www.contactus.gsk.com/callback/index.html","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsksource.com/pharma/content/gsk/source/us/en.html","http://www.msds-gsk.com/","https://www.gsk.com/en-gb/investors/shareholder-information/","http://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/investors/corporate-reporting/","https://www.gsk.com/en-gb/investors/product-pipeline/","http://www.gskgrants.com/","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsk.com/media/2941/human-rights-statement-policy.pdf","http://www.gsk.com/media/280848/human-rights-statement-policy.pdf","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","http://twitter.com/GSK","http://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/","http://www.gskforyou.com/","https://www.gskforyou.com/prescription-resource-assistance/immunology-respiratory/","https://www.contactus.gsk.com/callback.html","https://www.gsk.com/en-gb/about-us/governance/global-compliance/","https://www.gsk.com/en-gb/careers/physicians/","https://www.gsk.com/en-gb/contact-us/worldwide/","https://access.gsk.com/password/","https://access.gsk.com/selfservice/static/login.jsp?TYPE=33554433&REALMOID=06-c7edf5ec-5585-100d-83b1-84797f88fc89&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-90R5K5a0NsTyKRhPyTIn3A3B5ovKkqcehflGRUrUNusjZdRaPY%2bWUozEFizs1bMg&TARGET=-SM-https%3a%2f%2fuksah%2egsk%2ecom%2fswh_uk_win_ns%2fcommunications%2femployee%2femployees%2ehtm","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://ascend.cvmsolutions.com/Account/Login?client=gsk","https://www.gsk.com/media/5097/our-approach-to-responsible-business_sept-18.pdf","https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/","https://www.gsk.com/media/2538/gsk-materiality-process.pdf","https://www.gsk.com/en-gb/responsibility/access-to-healthcare/","https://www.gsk.com/en-gb/responsibility/our-people/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/","https://www.gsk.com/media/4552/our-code-of-practice.pdf","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=10","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/en-gb/media/resource-centre/","https://www.gsk.com/en-gb/media/image-and-video-library/","https://www.gsk.com/en-gb/media/rss-feeds/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2017/","https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/","https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/","https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/","https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/","https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/","https://www.gsk.com/en-gb/careers/experienced-professionals/sales/","https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf","https://www.gsk.com/en-gb/careers/meet-our-people/","https://www.gsk.com/en-gb/responsibility/our-people/employee-volunteering/","https://gskearlytalent.avature.net/landingpage","https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/","https://www.gsk.com/en-gb/responsibility/our-people/volunteer-stories/","https://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/","https://www.gsk.com/en-gb/research/our-approach/open-innovation/","https://www.youtube.com/channel/UChWuz9ZDceHYHXmJVJ4hF8Q","https://www.youtube.com/channel/UCN1XeWQWLVhFLHQwZl93jFQ","https://www.youtube.com/channel/UCwQyIfV4pLlsZGuN7fiZm2w","https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/","https://www.gsk.com/en-gb/careers/meet-our-people/lindsay-rd-uk/","http://uk.gsk.com/en-gb/careers/apprenticeships/","https://www.gsk.com/media/4931/gsk-quick-facts.pdf","https://ie.gsk.com/ie/careers/apprenticeships/","http://au.gsk.com/en-au/careers/apprenticeships/","http://sg.gsk.com/en-sg/careers/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/","https://gsk.i-sight.com/landing-page/","https://www.gskforyou.com/","https://privacy.gsk.com/en-ca/privacy-notice/general","http://annualreport.gsk.com/","https://privacy.gsk.com","https://www.gsk.com/en-gb/company/outstanding-people/","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/en-gb/behind-the-science/","https://gskpro.com/","https://viivhealthcare.com/","https://gsk.supplierone.co/","https://www.gsk.com/speakup","https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/","https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/en-gb/company/policy-positions","https://www.gsk.com/en-gb/company/codes-standards-and-reports","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk-studyregister.com","https://gskpro.com/en-ca/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://annualreport.gsk.com/","https://www.gsk.com/en-gb/media/media-contacts/","https://www.gsk.com/en-gb/media/media-library/","https://www.gsk.com/en-gb/media/social-media/","https://www.gsk.com/en-gb/media/our-response-to-the-situation-in-ukraine/","https://www.gsk.com/en-gb/careers/featured-careers/","https://www.gsk.com/en-gb/careers/how-we-hire/","https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/","https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/careers/early-talent/kickstart-your-career/","https://www.gsk.com/en-gb/careers/early-talent/apprentice-programmes/","https://www.gsk.com/en-gb/careers/early-talent/work-experience-placements-and-internships/","https://www.gsk.com/en-gb/company/governance/compliance/","https://gskpro.com","https://www.gsk-studyregister.com/","https://www.gsk.com/en-gb/company/gsk-at-a-glance/","https://www.gsk.com/en-gb/innovation/technologies/","https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/","https://www.gsk.com/en-gb/responsibility/","https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","https://privacy.gsk.com/en-ca/privacy-notice/","https://us.gsk.com/en-us/about-us/us-community-partnerships/stem-education/philadelphia-stem-equity-collective/","https://www.gsk.com/en-gb/responsibility/charitable-partnerships/","https://supplier.gsk.com/irj/portal/public","https://privacy.gsk.com/en-ca/privacy-notice/general/","https://twitter.com/gskca","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2022-performance-with-full-year-sales-of-293-billion/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/respiratoryimmunology/","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2023/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://supplier.gsk.com/"]},"settings":{"optionalStylesheetLink":"/media/bbcob5qx/optional_style_ca.css","themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=100&v=1dbf19a937d1f70","alt":"Gsk Logo Png","darkModeSrc":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=90&v=1dbf19a937d1f70"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK Canada"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://ca.gsk.com/en-ca/media/press-releases/health-canada-expands-jemperli-dostarlimab-for-injection/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null}